JOHNSON & JOHNSON — 13F Holdings & Portfolio
CIK 200406 · latest 13F-HR filed 2026-08-06
JOHNSON & JOHNSON manages $798.7M in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PTGX (37.59%), NBTX (26.55%), MGTX (11.23%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 2; 9 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-06
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 98.4%Cumulative share of the portfolio held in the largest N positions.
SUITE 3950
DENVER, CO 80202
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| B&W HOLDINGS LLC Control | MEMBER | 75% or more | Domestic Entity |
| BURKE, LISA, MARIE Control | CHIEF COMPLIANCE OFFICER | Less than 5% | Individual |
| CRAWFORD, PATRICK, CAIN Control | MANAGING DIRECTOR | Less than 5% | Individual |
| DOWELL, WILLIAM, F Control | MANAGING DIRECTOR | Less than 5% | Individual |
| HICKS, BRYANT Control | DIRECTOR OF OPERATIONS | Less than 5% | Individual |
| JOHNSON, BRANDON, CARROLL Control | ELECTED MANAGER & CEO | Less than 5% | Individual |
| JOHNSON, BRANDON, CARROLL Control | MEMBER | 50–75% | Individual |
| JOHNSON, WENDY, MARIE Control | GENERAL COUNSEL | Less than 5% | Individual |
| JOHNSON, WENDY, MARIE Control | MEMBER | 50–75% | Individual |
| KOONS, MARY, LOVE Control | MANAGING DIRECTOR | Less than 5% | Individual |
| LAWRENCE, ROBERT, LLOYD Control | SENIOR ADVISOR | 5–10% | Individual |
| WILLIAMS, ALBERT, WAYNE Control | MANAGING DIRECTOR | 5–10% | Individual |
| BRITISH COLONY INVESTMENT COMPANY, LLC | MEMBER | 5–10% | Domestic Entity |
| KEFFELER, KRISTIN | CHIEF LEARNING OFFICER | Less than 5% | Individual |
| MCCONNELL, MARK, PETER | MANAGING DIRECTOR | Less than 5% | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PROTAGONIST THERAPEUTICS INC$42.1M +16.3%
- NANOBIOTIX$38.4M +22.1%
- MEIRAGTX HLDGS PLC$32.2M +56.0%
- RAPPORT THERAPEUTICS INC$18.5M +33.2%
- LEGEND BIOTECH CORP$8.8M +59.6%
Top Trims
- CVRX INC-$17.4M -45.7%
- PROCEPT BIOROBOTICS CORP-$869.8K -9.7%
- NEUMORA THERAPEUTICS INC.-$462.4K -12.8%
- STANDARD BIOTOOLS INC-$30.1K -10.5%
JOHNSON & JOHNSON Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $300.2M | 37.59% | 2,449,183 | SH |
| 2 | NANOBIOTIX | NBTX | 63009J107 | $212.0M | 26.55% | 5,623,816 | SH |
| 3 | MEIRAGTX HLDGS PLC | MGTX | G59665102 | $89.7M | 11.23% | 6,641,064 | SH |
| 4 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $74.4M | 9.31% | 1,784,517 | SH |
| 5 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $32.4M | 4.06% | 1,979,173 | SH |
| 6 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $23.5M | 2.95% | 814,586 | SH |
| 7 | CVRX INC | CVRX | 126638105 | $20.7M | 2.59% | 4,024,861 | SH |
| 8 | XENCOR INC | XNCR | 98401F105 | $12.0M | 1.51% | 748,062 | SH |
| 9 | CEREBRAS SYSTEMS INC | CBRS | 15675D103 | $11.8M | 1.48% | 53,586 | SH |
| 10 | FATE THERAPEUTICS INC | FATE | 31189P102 | $9.1M | 1.14% | 3,379,064 | SH |
| 11 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $8.1M | 1.01% | 357,939 | SH |
| 12 | NEUMORA THERAPEUTICS INC. | NMRA | 640979100 | $3.1M | 0.39% | 1,849,445 | SH |
| 13 | VOR BIOPHARMA INC | VOR | 929033207 | $989.2K | 0.12% | 53,732 | SH |
| 14 | STANDARD BIOTOOLS INC | LAB | 34385P108 | $256.7K | 0.03% | 311,967 | SH |
| 15 | ADICET BIO INC | ACET | 007002207 | $196.8K | 0.02% | 22,779 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-06 | $798.7M | 15 | 0000904454-26-000435 |
| 2026-03-31 | 2026-05-13 | $652.4M | 16 | 0000904454-26-000280 |
| 2025-12-31 | 2026-03-18 | $555.0M | 17 | 0000904454-26-000192 |
| 2025-09-30 | 2026-03-18 | $503.9M | 20 | 0000904454-26-000190 |
NEW BRUNSWICK, NJ 08933